Douglas Hanahan

Douglas Hanahan is one of the most cited biomedical scientists alive, best known for co-authoring the "Hallmarks of Cancer" series with Robert Weinberg — a conceptual framework that has fundamentally organized how the scientific community understands cancer as a biological disease. His original 2000 paper in Cell has accumulated more than 45,000 citations, making it one of the most cited biomedical papers ever published. Hanahan trained under Walter Gilbert at Harvard and performed postdoctoral work that led to the development of transgenic mice expressing the SV40 large T antigen under the insulin promoter — the RIP-Tag mouse model. This model, which reliably develops pancreatic islet cell tumors through a defined multistep progression, became one of the most widely used experimental systems for studying tumor angiogenesis, tumor progression, and the therapeutic efficacy of anti-cancer agents in an intact mammalian host. Using the RIP-Tag model, Hanahan described the "angiogenic switch" — the discrete transition during tumor progression at which a pre-malignant lesion recruits new blood vessels, converting from a dormant state to rapid, vascularized expansion. This work provided mechanistic insight into Judah Folkman's angiogenesis hypothesis and identified specific pro-angiogenic signals (VEGF, FGF) as critical gating factors in tumor growth. The Hallmarks of Cancer framework, which Hanahan co-authored in 2000 and substantially expanded in 2011 and 2022, defined acquired biological capabilities — including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, invasion/metastasis, reprogrammed metabolism, and immune evasion — as universal features of human cancers. The 2022 update in Cancer Cell added emerging hallmarks including phenotypic plasticity, non-mutational epigenetic reprogramming, polymorphic microbiomes, and senescent cells. Hanahan is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the European Molecular Biology Organization.

Douglas Hanahan 是在世引用次数最多的生物医学科学家之一，以与 Robert Weinberg 共同撰写"癌症标志"系列而著称——这一概念框架从根本上重新组织了科学界对癌症作为生物学疾病的理解。他2000年在《细胞》上发表的原始论文已积累了超过45,000次引用，是有史以来引用次数最多的生物医学论文之一。 Hanahan 开发了 RIP-Tag 转基因小鼠模型，描述了"血管生成开关"——肿瘤进展中前恶性病变招募新血管的离散转变，为 Judah Folkman 的血管生成假说提供了机制洞察。 其"癌症标志"框架于2000年首次发布，在2011年和2022年大幅扩展，定义了人类癌症的普遍生物学能力，成为整个领域最具影响力的概念组织原则。